key: cord-0713292-7m9j6w3t authors: Gutierrez-Villagomez, Juan Manuel; Campos-García, Tonatiu; Molina-Torres, Jorge; López, Mercedes G.; Vázquez-Martínez, Juan title: Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) date: 2020-08-25 journal: J Phys Chem Lett DOI: 10.1021/acs.jpclett.0c01685 sha: b4a94cfcc35b7f8d7c8286009c92b1f899304a7b doc_id: 713292 cord_uid: 7m9j6w3t [Image: see text] The pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has quickly spread globally, infecting millions and killing hundreds of thousands of people. Herein, to identify potential antiviral agents, 97 natural amide-like compounds known as alkamides and piperamides were tested against SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp), and the human angiotensin-converting enzyme 2 (ACE2) using molecular docking and molecular dynamics simulations. The docking results showed that alkamides and dimeric piperamides from Piper species have a high binding affinity and potential antiviral activity against SARS-CoV-2. The absorption, distribution, metabolism, and excretion (ADME) profile and Lipinski’s rule of five showed that dimeric piperamides have druglikeness potential. The molecular dynamics results showed that pipercyclobutanamide B forms a complex with Mpro at a similar level of stability than N3-I. Our overall results indicate that alkamides and piperamides, and specifically pipercyclobutanamide B, should be further studied as compounds with SARS-CoV-2 antiviral properties. the maturation of proteins during the viral cycle. 5,10−13 Other viral proteins marked as targets include the RNA-dependent RNA polymerase (RdRp, Nsp12), crucial for the SARS-CoV-2 development cycle, 14, 15 and the angiotensin-converting enzyme 2 (ACE2), a human integral membrane glycoprotein highly expressed in the kidneys, heart, and pulmonary endothelium. 16 ,17 SARS-CoV-2 and other coronaviruses use ACE2 as a cellular entry receptor; specifically, the union of the spike protein S1 of SARS-CoV-2 to the enzymatic domain of ACE2 in the extracellular surface induces endocytosis and translocation of the virus-ACE2 protein complex. 18, 19 Therefore, inhibiting the active sites of Mpro, RdRp, and/or ACE2 is a potential approach for antiviral development. Compounds containing amide and aromatic groups, including the approved COVID-19 drug Remdesivir, are potential inhibitors of Mpro, RdRp, and/or ACE2. 5, 10, 11, 15, 20 In this regard, we evaluated the possible antiviral activity of natural, plant-derived, amide-like compounds known as alkamides and piperamides. Alkamides and piperamides are compounds structurally diverse comprised of aromatic, polysubstituted, polyunsaturated and dimeric compounds, generally synthesized from the enzymatic reaction between acyl chains and amino acid-derived compounds. 21−23 These compounds have shown bioactivity in viruses, bacteria, fungi, and animals including humans. 22,24−27 Thus, we explored the interaction between 97 alkamides and piperamides and Mpro, RdRp, and ACE2 using molecular docking simulations. Additionally, we study the interaction of the best-docked compound against Mpro using molecular dynamics (MD) simulations. The docking score energy values (DS) generated from the binding of Mpro and the compounds with the best DS are listed in Table 1 (see Table S1 ). The compounds with at least 70% of the Mpro native inhibitor (N3-I) DS values were considered as potential Mpro inhibitors. The best-docked compound against SARS-CoV-2 Mpro was pipercyclobutanamide B (DS = −7.827 kcal/mol) which is comparable to N3-I (DS = −7.348 kcal/mol). Other structures with considerable DS were pipercyclobutanamide A (DS = −7.244 kcal/mol), nigramide R (DS = −6.979 kcal/mol), chabamide K (DS = −6.381 kcal/mol), nigramide Q (DS = −5.968 kcal/mol), N-(2-phenylethyl)-3-phenyl-2E-propenamide (DS = −5.963 kcal/mol), chabamide J (DS = −5.713 kcal/mol), and chabamide I (DS = −5.346 kcal/mol). Figure 1 and Table 2 show the molecular interactions of N3-I and pipercyclobutanamide B with Mpro. N3-I fits into the pocket of the active site of Mpro ( Figure 1B ,C). As well, pipercyclobutanamide B fits into the Mpro pocket ( Figure 1E ,F), but on the opposite side of N3-I ( Figure 1B,C) . The N3-I binding is mainly via polar interactions, whereas pipercyclobutanamide B binds mainly through hydrophobic ones. Polar interactions are influenced mainly by amino and carbonyl groups ( Figure 1A ). The hydrophobic interactions are influenced mainly by aromatic rings and double bonds ( Figure 1D ). The dimeric piperamides in the Piper genus, 28, 29 had DS similarities to N3-I. Particularly, pipercyclobutanamides A and B had the highest DS and therefore the highest potential to interfere with Mpro. Both, N3-I and pipercyclobutanamide B dock through an Hbond to Gln-189 and polar interactions to Arg-188. Pipercyclobutanamide B stabilizes in the same pocket that N3-I, but with some differences due to polarity. The amino acids involved in the stabilization of N3-I and pipercyclobutanamide B are also involved in the interaction with other Mpro inhibitors such as rutin, ritonavir, emetine, and hesperidin. 30 As expected, N3-I binds to the crucial catalytic residues His-41 and Cys-145. 12 However, pipercyclobutanamide B interacts only with His-41 through polarhydrophobic interactions between the imidazole group of His-41 and the piperidine-carbonyl-enyl moiety of pipercyclobutanamide B. As shown in Figure 1 and Table 2 , N3-I and pipercyclobutanamide B also interact with other important residues of the active site such as Met-49, Gly-143, His-163, His-164, Glu-166, and Pro-168. 13, 18 The higher DS value of pipercyclobutanamide B over N3-I could be due to the interactions with the protein residues or the 3D configuration. Pipercyclobutanamide B has an X-form conformation that docks in an X-form protein pocket, ( Figure 1D −F). Pipercyclobutanamides A and B are considered trace constituents of black peppercorns (Piper nigrum) with less than 0.12% and 0.006% by dry weight, respectively. 28 However, these compounds can be fully synthesized. 31, 32 To our knowledge, this is the first report of dimeric-piperamides, specifically pipercyclobutanamides, as potential antivirals via inhibition of SARS-CoV-2 Mpro. The best-docked ligand against SARS-CoV-2 RdRp was the triphosphate form of GS-441524 (DS = −8.495 kcal/mol), the RdRp native inhibitor, that is metabolically derived from Remdesivir. None of the analyzed compounds reached 70% of the inhibitor DS value (Table 1) Table 2 . The molecular docking results showed that alkamides and piperamides are less effective against SARS-CoV-2 RdRp compared to SARS-CoV-2 Mpro. The alkamides/piperamides DS values did not reach that of the SARS-CoV-2 RdRp native inhibitor because of the triphosphate moiety in the GS-441524-TPP and its mimicry with the nucleotide triphosphates that are the RdRp native ligands. Also, the crystallized structure of RdRp shows that the Hbonds to Arg-553, Thr-687, and Asp-760 are important for its catalytic activity. 33 In the crystallized structure, the triphosphate moiety is hydrolyzed into 2pyrophosphate and the monophosphate-inhibitor form. Arg-553 forms two Hbonds to the β-phosphate of the free 2pyrophosphate, Asp-760 forms two Hbonds to the bonded αmonophosphate, and Thr-687 forms one more Hbond to the hydroxy group at the cyano-oxolane moiety. 33 After redocking the triphosphate form of the inhibitor, the phosphate groups remained as the docking points. The anchor residues change in the interaction importance since only Arg-553 remains to form an Hbond and Cys-622 along with Lys-621 binds via Hbonds to the beta-phosphate group. As expected, interactions with Mg-1004 are present in both crystallized and redocked inhibitor-protein complexes. 33 The tested compounds failed to reach a comparable DS to the SARS-CoV-2 RdRp inhibitor. However, some piperamides (present in Piper tuberculatum 34 ) had sufficient DS to warrant future research. 8,9-Dihydropiplartine and pipercyclobutanamide A were the best-docked compounds with similar DS. Both compounds coordinate with Mg-1004 through the Table 2 . The DS value of the DCBICA−human ACE2 complex was the highest overall, showing that DCBICA is a strong inhibitor of human ACE2. Similar to the SARS-CoV-2 Mpro and RdRp results, some piperamides could also be potential inhibitors of ACE2. No comparable residue interactions between the DCBICA and the piperamide ACE2 complexes were identified, reflecting their low DS. The considerable DS of piperamides could be due to the attachment between the 3D configuration of the docked ligands and the 3D configuration of the human ACE2 pocket. The protein pocket entrance-size also needs to be considered. Although the best-docked piperamides bound with regular DS, they may be too large to enter the human ACE2 pocket. In that case, other nondimeric alkamides or pipermides with lower DS and smaller size could be investigated (Table 1; i.e., N-isobutyl-(2E,4Z)-octadienamide and N-(2-phenylethyl)-cis-2,3-epoxynona-6,8-diynamide). The absorption, distribution, metabolism, and excretion (ADME) properties of the native inhibitors and the tested compounds with the highest DS for each protein are listed in Table 3 . According to their molecular properties, Lipinski's Rule of five (RO5) was used to evaluate the potential of these alkamides as orally active drugs in humans. 35 Additionally, the Jorgensen Rule of three (RO3) was used to evaluate the oral availability of the compounds. 36 The violations to the RO5 and RO3 are listed in Table 3 . The dimeric piperamides violate the rules of maximum molecular weight and/or permeability. However, they performed better than N3-I and GS-441524-TPP. Therefore, these piperamides have considerable drug potential, especially considering their favorable traits such as high oral absorption, brain/blood partition coefficient, predicted binding to human serum albumin, and activity in the central nervous system (Table 3) . We used MD simulations to explore the evolution of the complex ligand-Mpro through time. MD analysis is a very computationally demanding process, hence we selected pipercyclobutanamide B, the piperamide with the best docking results, and the native inhibitor (N3-I) for the analysis. The MD simulations results show that N3-I binds stably to the Mpro active site residues ( Figure 4A , Tables 4 and S2) . Similarly, the same Mpro residues in contact with the pipercyclobutanamide B maintained low RMSD changes, except for the 188 and 189 residues that increased their RMSD movement at the last nanosecond of the MD simulation ( Figure 4B , Tables 4 and S3). During the MD simulation, Mpro−ligand complexes were able to maintain low ligand movement below 3.5 Å and stabilize at an average of 2.5 Å after 1 ns. This indicates proximity and stronger binding for both compounds to the Mpro active site ( Figure 4C ). Protein movement RMSD stabilizes around 1.5 Å after 2 ns for both ligands, following similar trajectories ( Figure 4D ). Additionally, small conformational changes were observed for protein and ligands during MD simulation ( Figure 4E,F) . The active site residues contact number for Mpro−N3-I and Mpro− pipercyclobutanamide B complexes show a similar level of protein−ligand interaction during the simulation for both ligands ( Figure 4G) . A contact between two molecules is defined when the heavy atom of one molecule is within a cutoff distance from the heavy atom of another molecule. 37 The contact fingerprint of Mpro with pipercyclobutanamide B shows that, during the 5.5 ns of the MD simulation, the ligand had contacts with all the heavy atoms from the protein backbone with most of the amino acids that form the binding pocket ( Figure 4G ). On average, pipercyclobutanamide B contacts increased with Glu-166, His-163, and Asn-142 compared to N3-I ( Figure 4G ), amino acids that belong to the binding pocket subunit S1. 12 Ligand−protein interactions with amino acids in the subunit S1 such as Glu-166 and His-163 are important interactions with inhibitors like cinancerin, nelfinavir, pralmorelin, and N3. 12, 38 Also, the residue His-41 that belongs to the Mpro catalytic dyad increased the number of contacts as well as Met-49, Met-165, and Asp-187 that belong to the binding pocket subsite S2, 12 while Cyst-145 contacts remain similar as N3-I ( Figure 4G ). The molecular docking results for SARS-CoV-2 Mpro and RdRp, and human ACE2 indicate that some alkamides and piperamides have high antiviral potential against SARS-CoV-2, especially, the dimeric piperamides of P. nigrum and Piper chaba. The phenethyl-alkamides found in the Acmella genus may also interact considerably with these three proteins. The capsaicinoids of the Capsicum genus and major piperamides of P. nigrum (piperine and trichostachine) affect RdRp in particular. The potential anti-SARS-CoV-2 activity of the tested compounds is linked mainly to interference with the The Journal of Physical Chemistry Letters pubs.acs.org/JPCL Letter Mpro function. Therefore, the effect of piperine-enriched essential oils of Piper species and piperamide-like purified compounds should be examined in vitro and in vivo. The ADME studies further support the anti-SARS-CoV-2 potential of the dimeric piperamides from Piper species, primarily against the main protease (Mpro) of SARS-CoV-2, but also considerably against SARS-CoV-2 RdRp and the human ACE2. The MD simulations showed that pipercyclobutanamide B forms a complex with Mpro with similar stability to N3-I, indicating a promising performance for future in vitro and in vivo experiments. Then, piperamides and related compounds should be considered for a possible alkamide/ piperamide-based treatment. Many of the examined compounds have common culinary uses, including the piperamides and capsaicinoids found in the common pepper (P. nigrum) and chili pepper (Capsicum annuum), respectively. Possible mitigating effects of an alkamide/piperamide-rich diet on coronavirus susceptibility should be studied. Based on past and herein presented data, amide-aromatic-like natural products could potentially act as antivirals against SARS-CoV-2 and related coronaviruses. These results show the potential of dimeric piperamides, specifically pipercyclobutanamide B, as antivirals against SARS-CoV-2. The SARS-CoV-2 Mpro (PDB ID: 6LU7; resolution 2.14 Å), 12 the SARS-CoV-2 RdRp (PDB ID: 7BV2; resolution 2.5 Å), 33 States were minimized converging heavy atoms to RMSD of 0.3 Å and an OPLS3e option force field. All other parameters were set to default values. The RdRp and ACE2 proteins were prepared following the same steps as for 6LU7 but with the following considerations. For 7BV2, only the chain A (888 amino acids) was used and the RNA molecule was deleted to avoid incorrect interactions during docking simulations. For 1R4L, the chain A (782 amino acids) was used. Each protein was prepared on a separate project to facilitate the results inspection. Based on published literature and to cover a variety of chemical structures, 97 alkamides and piperamides were selected and retrieved from PubChem. The structures of the Mpro, RdRp, and ACE2 inhibitors were retrieved from PubChem. All structures are listed in Supporting Information Tables S1 and SMILES, including their respective PubChem ID. All ligands were prepared by generating states at a pH of 7.0 with desalt and generating tautomers options. There were generated for each ligand at most 32 possible states using the OPLS3e force field option. 25 The compounds that did not have interaction with Mpro, RdRp, and ACE2 were not included in the results in Table 1 . However, they were included in Supporting Information Table S1, since negative results have a scientific value. The molecular docking was performed between each protein and ligand using the Grid-Based Ligand Docking with Energetics (GLIDE) module of Maestro Schrodinger software. The grids for each protein was generated using the Grid Generation tool. 25 Molecular dynamics simulations were run using the Largescale Atomic/Molecular Massively Parallel Simulator code (LAMMPS) and using CHARMM36 additive force field for protein as well as protein−ligand complexes. 45, 46 The system was minimized with the Polak−Ribiere version of the conjugate gradient (CG) algorithm and then equilibrated applying bond and angle constraints to specified bonds and angles in the simulation with the SHAKE algorithm 47 and the canonical NVT ensemble. The production of MD simulations was performed at a constant temperature of 310.15 K and a constant pressure of 1 bar using the isothermal−isobaric ensemble (constant temperature and constant pressure ensemble). All the simulations input scripts were generated with the CHARM-GUI Solution Builder. 48, 49 To generate the input files for simulations and prepare the solvent system, we used the interactive web-based platform CHARMM-GUI. 50 The protein−ligand complexes were placed in an octahedral waterbox with a 5.0 Å of edge distance, 0.1 M KCl ions, and the Monte Carlo ion placing method. 48 The simulations were conducted for 5.55 ns and performed on a workstation with Windows 10 Pro 64 bits, AMD Threadripper 1950X, 16 cores, 64 GB RAM. The stability of the protein and protein−ligand complex system was analyzed by calculating the root-meansquare deviation (RMSD) and root-mean-square fluctuation (RMSF) using the Bio3d package in R-Studio. 51, 52 A contact analysis between the residues in the binding pocket (residues 40−190) and the corresponding ligand was made with the Timeline plugin (V.2.3) in the Visual Molecular Dynamics (VMD) software and the heatmaps were constructed with the data matrix extracted from the RMSD Visualizer Tool plugin in VMD. The representations in structural conformation differences showed in Figure 4 were made with PyMol. 53 The RcolorBrewer pallet was used to assign color blind-friendly colors to the graphs. 54 ■ ASSOCIATED CONTENT * sı Supporting Information The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jpclett.0c01685. SARS-CoV-2, severe acute respiratory syndrome coronavirus COVID-19, associated syndrome of SARS-CoV-2 SARS-CoV-2 main protease; Nsp5, nonstructural protein 5 RNA-dependent RNA polymerase -methyl-1,2-oxazol-3-yl)-carbonyl 2-{1-carboxy-2-[3-(3,5-dichloro-benzyl)-3H-imidazol-4-yl]-ethylamino}-4-methyl-pentanoic acid) ADME, favorable absorption, distribution, metabolism, and excretion Coronavirus Infections-More Than Just the Common Cold Coronavirus as a Possible Cause of Severe Acute Respiratory Syndrome Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia A Novel Coronavirus from Patients with Pneumonia in China Alpha-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment Johns Hopkins Coronavirus Resource Center Milken Institute. COVID-19 Treatment and Vaccine Tracker Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved Alpha-Ketoamide Inhibitors Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design Structure of M(pro) from SARS-CoV-2 and Discovery of Its Inhibitors Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp): A Molecular Docking Study A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1−9 Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis Silico Identification of Potent FDA Approved Drugs against Coronavirus COVID-19 Main Protease: A Drug Repurposing Approach Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Coronavirus Natural Alkamides: Pharmacology, Chemistry and Distribution Natural and Synthetic Alkamides: Applications in Pain Therapy Alkamid Database: Chemistry, Occurrence and Functionality of Plant N-Alkylamides Antimicrobial Properties of Alkamides Present in Flavouring Plants Traditionally Used in Mesoamerica: Affinin and Capsaicin Bioautography and GC-MS Based Identification of Piperine and Trichostachine as the Active Quorum Quenching Compounds in Black Pepper Anti-Inflammatory Effects of Ethanolic Extract and Alkamides-Derived from Heliopsis Longipes Roots Alkamides Isolated from Plants Promote Growth and Alter Root Development in Arabidopsis Two New Alkaloids, Pipercyclobutanamides A and B, from Piper Nigrum Novel Dimeric Amide Alkaloids from Piper Chaba Hunter: Isolation, Cytotoxic Activity, and Their Biomimetic Synthesis An Investigation into the Identification of Potential Inhibitors of SARS-CoV-2 Main Protease Using Molecular Docking Study Sequential C□H Arylation and Olefination: Total Synthesis of the Proposed Structure of Pipercyclobutanamide A Stereoselective Preparation of Cyclobutanes with Four Different Substituents: Total Synthesis and Structural Revision of Pipercyclobutanamide A and Piperchabamide G Structural Basis for Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir Piperamides and Their Derivatives as Potential Anti-Trypanosomal Agents Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings QikProp 3.4 User Manual Amino Acid Empirical Contact Energy Definitions for Fold Recognition in the Space of Contact Maps Identification of Potential Mpro Inhibitors for the Treatment of COVID-19 by Using Systematic Virtual Screening Approach Structures Reveal a Large Hinge-Bending Motion Important for Inhibitor Binding and Catalysis 41) Schrodinger. Glide; Schrodinger LLC Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening Fast Parallel Algorithms for Short-Range Molecular Dynamics Using Collective Variables to Drive Molecular Dynamics Simulations Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field CHARMM-GUI Supports the Amber Force Fields A Web-Based Graphical User Interface for CHARMM Bio3d: An R Package for the Comparative Analysis of Protein Structures RStudio Team. RStudio Integrated Development Environment for R The PyMOL Molecular Graphics System. Schrodinger, LLC. (54) Neuwirth, E. RColorBrewer: ColorBrewer Palettes The authors declare no competing financial interest. We would like to thank Wo Su Zhang and Enrique Ramı́rez-Chavez for proofreading and providing helpful feedback that improved the manuscript. We acknowledge with appreciation the computational support from Dr. Frederick Ayala-Goḿez. The authors would like to thank SNI-CONACyT, ITESI, and CINVESTAV-Irapuato for support.